Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MOMETASONE FUROATE

All products: general benefit

Other products in the same Health Canada class (D07AC) — coverage varies; not interchangeable

  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate (Diprosone): general benefit
  • Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit
  • Betamethasone valerate (Betnovate-1/2): general benefit, Not a benefit

8 more in the class list below

Elocom · DIN 00851736 · 0.1% · Oint

General benefitMarketed · checked 2026-09-19
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists Elocom (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Elocom · DIN 00851736 Manufacturer: Organon Canada Inc.; listing date 1996-10-01 Health Canada: Marketed since 2022-08-18 · brand ELOCOM · ATC D07AC13 MOMETASONE · form Ointment · route Topical · ingredients MOMETASONE FUROATE 0.1 % · company Product excellence inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2252 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11444 · Verify on the e-Formulary ↗ (DIN 00851736)

Source record
DIN 00851736: Elocom Raw flags: sec3=Y Item: 840600110; group id 849; item number 2066; lccId None; manufacturer id OCI Source form: Oint; strength: 0.1% Recorded listing: General benefit Source prices (unrounded): $0.7342; ministry $0.2252 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00851736 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11444
Interchangeable products
Ratio-Mometasone · DIN 02248130 · $0.2252
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

DESONIDE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.05% · Cr, Oint

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications ELOCOM® (mometasone furoate) Cream, Ointment and Lotion 0.1%: • are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid- responsive dermatoses such as psoriasis and atopic dermatitis. The lotion formulation may be applied to scalp lesions. • can be used for a maximum of 3 weeks duration on the body and of 5 days duration on the face, scalp, axillae and scrotum. 1.1. Pediatrics Pediatrics (<18 years of age): Safety and efficacy of ELOCOM have not been established in pediatric patients (see 7. Warnings and Precautions, 7.1. Special Populations, 7.1.3. Pediatrics). 1.2. Geriatrics Geriatrics (≥ 65 years of age): No overall differences in safety and effectiveness were observed between subjects greater than 65 years of age and younger subjects receiving ELOCOM Cream or Ointment. Clinical trials of ELOCOM Lotion did not include sufficient numbers of subjects aged 65 years and older to determine whether they respond differently from younger subjects. Geriatric patients may be more susceptible to the potential effects of systemic absorption. Decreased hepatic or renal function in the elderly may delay elimination (see … https://pdf.hres.ca/dpd_pm/00081816.PDF PM date: 2025-09-19 Source product: ELOCOM; DIN 00851736; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.